PCG
NBIX icon

Private Capital Group’s Neurocrine Biosciences NBIX Stock Holding History

Private Capital Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$37K Sell
384
-317
-45% -$29.3K 0.03% 590
2022
Q1 		$66K Buy
701
+257
+58% +$21.8K 0.02% 543
2021
Q4 		$38K Sell
444
-159
-26% -$14.6K 0.01% 800
2021
Q3 		$58K Buy
603
+299
+98% +$28.2K 0.01% 617
2021
Q2 		$30K Sell
304
-59
-16% -$5.66K 0.01% 894
2021
Q1 		$35K Sell
363
-67
-16% -$7.03K 0.01% 790
2020
Q4 		$41K Sell
430
-119
-22% -$11.5K 0.01% 888
2020
Q3 		$53K Buy
549
+211
+62% +$24.4K 0.01% 682
2020
Q2 		$41K Buy
338
+24
+8% +$2.65K 0.01% 808
2020
Q1 		$27K Buy
314
+61
+24% +$5.97K 0.01% 894
2019
Q4 		$27K Buy
253
+55
+28% +$5.76K 0.01% 990
2019
Q3 		$18K Buy
198
+161
+435% +$15K ﹤0.01% 1237
2019
Q2 		$4K Sell
37
-166
-82% -$13.6K ﹤0.01% 1710
2019
Q1 		$18K Buy
+203
New +$17K ﹤0.01% 1255
2018
Q3 		– Sell
-37
Closed -$3K – 2261
2018
Q2 		$3K Hold
37
– – ﹤0.01% 1806
2018
Q1 		$3K Sell
37
-218
-85% -$18.4K ﹤0.01% 1759
2017
Q4 		$8 Buy
+255
New +$17.4K ﹤0.01% 1459

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Private Capital Group's NBIX Position: Q2 2022 in Review

Private Capital Group reduced its Neurocrine Biosciences (NBIX) stake by 45% in Q2 2022, selling an estimated $29.3K and leaving 384 shares worth $37K. The position accounts for 0.03% of the portfolio, ranked #590.

Private Capital Group first reported a position in NBIX in Q4 2017 and has held it in 17 quarters since. The position peaked at $66K in Q1 2022. 438 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

  • Private Capital Group held 384 shares of Neurocrine Biosciences worth $37K as of Q2 2022.
  • Private Capital Group sold 317 Neurocrine Biosciences shares in Q2 2022, an estimated $29.3K.
  • Neurocrine Biosciences made up 0.03% of Private Capital Group's portfolio in Q2 2022, its #590 holding.
  • Private Capital Group first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 17 quarters since.
  • Private Capital Group's Neurocrine Biosciences position peaked at $66K in Q1 2022.
  • 438 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.